Disclosures for "Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design"
-
Dr. Mystkowski has received personal compensation for serving as an employee of Novo Nordisk. Dr. Mystkowski has stock in Novo Nordisk.
-
Dr. Johannsen has received personal compensation for serving as an employee of Novo Nordisk. Dr. Johannsen has stock in Novo Nordisk.
-
Marie Bentsen has received personal compensation for serving as an employee of Novo Nordisk.
-
Dr. Attfield has nothing to disclose.
-
Dr. FREDERIKSEN has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer (Nature). Dr. FREDERIKSEN has received research support from AP Møller Fonden. Dr. FREDERIKSEN has received publishing royalties from a publication relating to health care.
-
Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Frisoni has received research support from Novo Nordisk.
-
Dr. Jeppesen has received personal compensation for serving as an employee of Novo Nordisk. Dr. Jeppesen has stock in Novo Nordisk.
-
Dr. Malik has received personal compensation for serving as an employee of Novonordisk. Dr. Malik has stock in Novonordisk. Dr. Malik has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Knudsen has stock in Novo Nordisk. Dr. Knudsen has received intellectual property interests from a discovery or technology relating to health care.